{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:11:30Z","timestamp":1791141090583,"version":"4.1.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04236-z","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:24:44Z","timestamp":1772259884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulatory roles of microRNAs in signaling pathways and their biomarker potential in prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Hossein","family":"Kalarestaghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Amani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Shoorei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"4236_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-019-0448-6","volume":"19","author":"J Smith-Palmer","year":"2019","unstructured":"Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019;19:1\u201316.","journal-title":"BMC Urol"},{"key":"4236_CR2","doi-asserted-by":"crossref","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. bmj 2018, 362.","DOI":"10.1136\/bmj.k3519"},{"issue":"1","key":"4236_CR3","first-page":"55","volume":"25","author":"C Stephan","year":"2014","unstructured":"Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K. Prostate-specific antigen (PSA) screening and new biomarkers for prostate cancer (PCa). Ejifcc. 2014;25(1):55.","journal-title":"Ejifcc"},{"issue":"17","key":"4236_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730.","journal-title":"Molecules"},{"issue":"3","key":"4236_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030380","volume":"13","author":"N Arrighetti","year":"2021","unstructured":"Arrighetti N, Beretta GL. miRNAs as therapeutic tools and biomarkers for prostate cancer. Pharmaceutics. 2021;13(3):380.","journal-title":"Pharmaceutics"},{"issue":"8","key":"4236_CR6","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.3390\/ijms140816010","volume":"14","author":"AQ Gomes","year":"2013","unstructured":"Gomes AQ, Nolasco S, Soares H. Non-coding RNAs: multi-tasking molecules in the cell. Int J Mol Sci. 2013;14(8):16010\u201339.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4236_CR7","first-page":"161","volume":"2","author":"AM Ardekani","year":"2010","unstructured":"Ardekani AM, Naeini MM. The role of microRNAs in human diseases. Avicenna J Med Biotechnol. 2010;2(4):161.","journal-title":"Avicenna J Med Biotechnol"},{"issue":"1","key":"4236_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/carcin\/bgl185","volume":"28","author":"H Osada","year":"2007","unstructured":"Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007;28(1):2\u201312.","journal-title":"Carcinogenesis"},{"key":"4236_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1755-8794-7-53","volume":"7","author":"RA Rawlings-Goss","year":"2014","unstructured":"Rawlings-Goss RA, Campbell MC, Tishkoff SA. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genom. 2014;7:1\u201314.","journal-title":"BMC Med Genom"},{"key":"4236_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-42059-2_1","volume-title":"Non-coding RNAs colorectal cancer","author":"S Hombach","year":"2016","unstructured":"Hombach S, Kretz M. Non-coding RNAs: classification, biology and functioning. In: Non-coding RNAs colorectal cancer. 2016. p. 3\u201317."},{"key":"4236_CR11","doi-asserted-by":"crossref","unstructured":"Sempere LF. Celebrating 25 years of microRNA research: From discovery to clinical application. In., vol. 20: MDPI; 2019: 1987.","DOI":"10.3390\/ijms20081987"},{"key":"4236_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13402-017-0341-9","volume":"40","author":"GS Markopoulos","year":"2017","unstructured":"Markopoulos GS, Roupakia E, Tokamani M, Chavdoula E, Hatziapostolou M, Polytarchou C, Marcu KB, Papavassiliou AG, Sandaltzopoulos R, Kolettas E. A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol. 2017;40:303\u201339.","journal-title":"Cell Oncol"},{"issue":"1","key":"4236_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1469-185X.2008.00061.x","volume":"84","author":"N Lynam-Lennon","year":"2009","unstructured":"Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev. 2009;84(1):55\u201371.","journal-title":"Biol Rev"},{"issue":"6","key":"4236_CR14","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.fertnstert.2013.10.042","volume":"101","author":"JM Moreno-Moya","year":"2014","unstructured":"Moreno-Moya JM, Vilella F, Sim\u00f3n C. MicroRNA: key gene expression regulators. Fertil Steril. 2014;101(6):1516\u201323.","journal-title":"Fertil Steril"},{"issue":"1","key":"4236_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/2211536607666180827111633","volume":"8","author":"M Tafrihi","year":"2019","unstructured":"Tafrihi M, Hasheminasab E. MiRNAs: biology, biogenesis, their web-based tools, and databases. Microrna. 2019;8(1):4\u201327.","journal-title":"Microrna"},{"key":"4236_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1134\/S106816202001015X","volume":"46","author":"I Zaporozhchenko","year":"2020","unstructured":"Zaporozhchenko I, Rykova EY, Laktionov P. The fundamentals of miRNA biology: structure, biogenesis, and regulatory functions. Russ J Bioorg Chem. 2020;46:1\u201313.","journal-title":"Russ J Bioorg Chem"},{"issue":"1","key":"4236_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna8010010","volume":"8","author":"AL Leit\u00e3o","year":"2022","unstructured":"Leit\u00e3o AL, Enguita FJ. A structural view of miRNA biogenesis and function. Non-coding RNA. 2022;8(1):10.","journal-title":"Non-coding RNA"},{"issue":"3","key":"4236_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/bit.28029","volume":"119","author":"V Rani","year":"2022","unstructured":"Rani V, Sengar RS. Biogenesis and mechanisms of microRNA-mediated gene regulation. Biotechnol Bioeng. 2022;119(3):685\u201392.","journal-title":"Biotechnol Bioeng"},{"issue":"5","key":"4236_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052805","volume":"23","author":"B Smolarz","year":"2022","unstructured":"Smolarz B, Durczy\u0144ski A, Romanowicz H, Szy\u0142\u0142o K, Hogendorf P. miRNAs in cancer (review of literature). Int J Mol Sci. 2022;23(5):2805.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4236_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/brv.12428","volume":"93","author":"SP Kabekkodu","year":"2018","unstructured":"Kabekkodu SP, Shukla V, Varghese VK, D\u2019Souza J, Chakrabarty S, Satyamoorthy K. Clustered miRNAs and their role in biological functions and diseases. Biol Rev. 2018;93(4):1955\u201386.","journal-title":"Biol Rev"},{"issue":"1","key":"4236_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01376-4","volume":"15","author":"F Yuan","year":"2024","unstructured":"Yuan F, Hu Y, Lei Y, Jin L. Recent progress in microRNA research for prostate cancer. Discover Oncology. 2024;15(1):480.","journal-title":"Discover Oncology"},{"key":"4236_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2017.00046","volume":"4","author":"K Zhou","year":"2017","unstructured":"Zhou K, Liu M, Cao Y. New insight into microRNA functions in cancer: oncogene\u2013microRNA\u2013tumor suppressor gene network. Front Mol Biosci. 2017;4:46.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"4236_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/2211536611201010034","volume":"1","author":"J-L Su","year":"2012","unstructured":"Su J-L, Chen P-S, Johansson G, Kuo M-L. Function and regulation of let-7 family microRNAs. Microrna. 2012;1(1):34\u20139.","journal-title":"Microrna"},{"issue":"15","key":"4236_CR24","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/sj.emboj.7601790","volume":"26","author":"C Le Sage","year":"2007","unstructured":"Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR\u2010222 promotes cancer cell proliferation. EMBO J. 2007;26(15):3699\u2013708.","journal-title":"EMBO J"},{"key":"4236_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.mrrev.2019.05.005","volume":"781","author":"J Cozar","year":"2019","unstructured":"Cozar J, Robles-Fernandez I, Rodriguez-Martinez A, Puche-Sanz I, Vazquez-Alonso F, Lorente J, et al. The role of miRNAs as biomarkers in prostate cancer. Mutat Res. 2019;781:165\u201374.","journal-title":"Mutat Res"},{"key":"4236_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-016-0556-9","volume":"15","author":"Y Wang","year":"2016","unstructured":"Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016;15:1\u201311.","journal-title":"Mol Cancer"},{"key":"4236_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110354","volume":"95","author":"Q-q Luo","year":"2022","unstructured":"Luo Q-q, Tian Y, Qu G-j, Luo S-s. Functional mechanism and clinical implications of miR-141 in human cancers. Cell Signal. 2022;95:110354.","journal-title":"Cell Signal"},{"issue":"6","key":"4236_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1432-0436.2008.00277.x","volume":"76","author":"GS Prins","year":"2008","unstructured":"Prins GS, Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation. 2008;76(6):641\u201359.","journal-title":"Differentiation"},{"issue":"1","key":"4236_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao Y-T, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1):198.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4236_CR30","volume":"2013","author":"HB da Silva","year":"2013","unstructured":"da Silva HB, Amaral EP, Nolasco EL, de Victo NC, Atique R, Jank CC, et al. Dissecting major signaling pathways throughout the development of prostate cancer. Prostate Cancer. 2013;2013(1):920612.","journal-title":"Prostate Cancer"},{"issue":"7","key":"4236_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073528","volume":"22","author":"T Akoto","year":"2021","unstructured":"Akoto T, Saini S. Role of exosomes in prostate cancer metastasis. Int J Mol Sci. 2021;22(7):3528.","journal-title":"Int J Mol Sci"},{"key":"4236_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111657","volume":"139","author":"A Boye","year":"2021","unstructured":"Boye A. A cytokine in turmoil: transforming growth factor beta in cancer. Biomed Pharmacother. 2021;139:111657.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4236_CR33","doi-asserted-by":"publisher","first-page":"e88533","DOI":"10.1371\/journal.pone.0088533","volume":"9","author":"G Ascolani","year":"2014","unstructured":"Ascolani G, Li\u00f2 P. Modeling TGF-\u03b2 in early stages of cancer tissue dynamics. PLoS One. 2014;9(2):e88533.","journal-title":"PLoS One"},{"issue":"11","key":"4236_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112767","volume":"20","author":"Y Hao","year":"2019","unstructured":"Hao Y, Baker D, Ten Dijke P. TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 2019;20(11):2767.","journal-title":"Int J Mol Sci"},{"key":"4236_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cellsig.2018.09.002","volume":"52","author":"A Vander Ark","year":"2018","unstructured":"Vander Ark A, Cao J, Li X. TGF-\u03b2 receptors: in and beyond TGF-\u03b2 signaling. Cell Signal. 2018;52:112\u201320.","journal-title":"Cell Signal"},{"issue":"3","key":"4236_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030487","volume":"10","author":"K Tzavlaki","year":"2020","unstructured":"Tzavlaki K, Moustakas A. Tgf-\u03b2 signaling. Biomolecules. 2020;10(3):487.","journal-title":"Biomolecules"},{"issue":"9","key":"4236_CR37","doi-asserted-by":"publisher","first-page":"a022061","DOI":"10.1101\/cshperspect.a022061","volume":"8","author":"A Hata","year":"2016","unstructured":"Hata A, Chen Y-G. Tgf-\u03b2 signaling from receptors to Smads. Cold Spring Harb Perspect Biol. 2016;8(9):a022061.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4236_CR38","doi-asserted-by":"publisher","unstructured":"Finnson KW, Almadani Y, Philip A. Non-canonical (non-SMAD2\/3) TGF-\u03b2 signaling in fibrosis: Mechanisms and targets. Semin Cell Dev Biol. 2020;101:115\u201322.https:\/\/doi.org\/10.1016\/j.semcdb.2019.11.013.","DOI":"10.1016\/j.semcdb.2019.11.013"},{"issue":"6","key":"4236_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/abbs\/gmq038","volume":"42","author":"Y Pang","year":"2010","unstructured":"Pang Y, Young CY, Yuan H. Micrornas and prostate cancer. Acta Biochim Biophys Sin. 2010;42(6):363\u20139.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"9","key":"4236_CR40","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1158\/1078-0432.CCR-13-1588","volume":"20","author":"X Li","year":"2014","unstructured":"Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, Meng D, Du W, Huang Y, Wu H. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res. 2014;20(9):2312\u201325.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4236_CR41","first-page":"57","volume":"41","author":"Y Tang","year":"2019","unstructured":"Tang Y, Wu B, Huang S, Peng X, Li X, Huang X, Zhou W, Xie P, He P. Downregulation of miR-505-3p predicts poor bone metastasis-free survival in prostate cancer. Oncol Rep. 2019;41(1):57\u201366.","journal-title":"Oncol Rep"},{"issue":"6","key":"4236_CR42","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/bjc.2014.48","volume":"110","author":"H Hirata","year":"2014","unstructured":"Hirata H, Hinoda Y, Shahryari V, Deng G, Tanaka Y, Tabatabai Z, Dahiya R. Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer. 2014;110(6):1645\u201354.","journal-title":"Br J Cancer"},{"issue":"7","key":"4236_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0807-3","volume":"9","author":"S Huang","year":"2018","unstructured":"Huang S, Wa Q, Pan J, Peng X, Ren D, Li Q, et al. Transcriptional downregulation of miR-133b by REST promotes prostate cancer metastasis to bone via activating Tgf-\u03b2 signaling. Cell Death Dis. 2018;9(7):779.","journal-title":"Cell Death Dis"},{"issue":"31","key":"4236_CR44","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1038\/onc.2013.374","volume":"33","author":"S Mishra","year":"2014","unstructured":"Mishra S, Deng JJ, Gowda PS, Rao MK, Lin C-L, Chen CL, Huang T, Sun L-Z. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene. 2014;33(31):4097\u2013106.","journal-title":"Oncogene"},{"key":"4236_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2018.01.031","volume":"418","author":"X Li","year":"2018","unstructured":"Li X, Li J, Cai Y, Peng S, Wang J, Xiao Z, Wang Y, Tao Y, Leng Q, Wu D. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. Cancer Lett. 2018;418:211\u201320.","journal-title":"Cancer Lett"},{"issue":"42","key":"4236_CR46","doi-asserted-by":"publisher","first-page":"72835","DOI":"10.18632\/oncotarget.20427","volume":"8","author":"Y Yang","year":"2017","unstructured":"Yang Y, Ji C, Guo S, Su X, Zhao X, Zhang S, Liu G, Qiu X, Zhang Q, Guo H. The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways. Oncotarget. 2017;8(42):72835.","journal-title":"Oncotarget"},{"issue":"8","key":"4236_CR47","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/bjc.2013.125","volume":"108","author":"K Ueno","year":"2013","unstructured":"Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai Z, et al. MicroRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013;108(8):1659\u201367.","journal-title":"Br J Cancer"},{"issue":"1","key":"4236_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00934-y","volume":"7","author":"B Zhou","year":"2022","unstructured":"Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7(1):95.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4236_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther. 2024;9(1):128.","journal-title":"Signal Transduct Target Ther"},{"key":"4236_CR50","first-page":"1","volume-title":"Notch signaling: methods protocols","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto S, Schulze KL, Bellen HJ. Introduction to Notch signaling. In: Notch signaling: methods protocols. 2014. p. 1\u201314."},{"issue":"7","key":"4236_CR51","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/carcin\/bgt127","volume":"34","author":"KM Capaccione","year":"2013","unstructured":"Capaccione KM, Pine SR. The notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34(7):1420\u201330.","journal-title":"Carcinogenesis"},{"issue":"6","key":"4236_CR52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1432-0436.2008.00288.x","volume":"76","author":"KG Leong","year":"2008","unstructured":"Leong KG, Gao WQ. The notch pathway in prostate development and cancer. Differentiation. 2008;76(6):699\u2013716.","journal-title":"Differentiation"},{"issue":"7","key":"4236_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrurol.2013.110","volume":"10","author":"L Marignol","year":"2013","unstructured":"Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol. 2013;10(7):405\u201313.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"4236_CR54","first-page":"432","volume":"4","author":"M Kashat","year":"2012","unstructured":"Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y, Sarkar FH. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res. 2012;4(4):432.","journal-title":"Am J Transl Res"},{"issue":"1","key":"4236_CR55","first-page":"793","volume":"16","author":"Q Sun","year":"2018","unstructured":"Sun Q, Weng D, Li K, Li S, Bai X, Fang C, Luo D, Wu P, Chen G, Wei J. MicroRNA\u2013139\u20135P inhibits human prostate cancer cell proliferation by targeting Notch1. Oncol Lett. 2018;16(1):793\u2013800.","journal-title":"Oncol Lett"},{"issue":"5","key":"4236_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050964","volume":"13","author":"S Bauer","year":"2021","unstructured":"Bauer S, Ratz L, Heckmann-Noetzel D, Kaczorowski A, Hohenfellner M, Kristiansen G, et al. MiR-449a repression leads to enhanced Notch signaling in TMPRSS2: ERG fusion positive prostate cancer cells. Cancers. 2021;13(5):964.","journal-title":"Cancers"},{"issue":"1","key":"4236_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13279-x","volume":"12","author":"L Rios-Colon","year":"2022","unstructured":"Rios-Colon L, Chijioke J, Niture S, Afzal Z, Qi Q, Srivastava A, et al. Leptin modulated microRNA-628-5p targets Jagged-1 and inhibits prostate cancer hallmarks. Sci Rep. 2022;12(1):10073.","journal-title":"Sci Rep"},{"issue":"2","key":"4236_CR58","first-page":"165","volume":"4","author":"PY Yip","year":"2015","unstructured":"Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):165.","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"4236_CR59","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/C5MB00101C","volume":"11","author":"T Ersahin","year":"2015","unstructured":"Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K\/AKT\/mTOR interactive pathway. Mol Biosyst. 2015;11(7):1946\u201354.","journal-title":"Mol Biosyst"},{"issue":"39","key":"4236_CR60","doi-asserted-by":"publisher","first-page":"8083","DOI":"10.2174\/0929867328666210804091548","volume":"28","author":"B ul Islam","year":"2021","unstructured":"ul Islam B, Suhail M, Khan MS, Ahmad A, Zughaibi TA, Husain FM, Rehman MT, Tabrez S. Flavonoids and PI3K\/Akt\/mTOR signaling cascade: a potential crosstalk in anticancer treatment. Curr Med Chem. 2021;28(39):8083\u201397.","journal-title":"Curr Med Chem"},{"issue":"12","key":"4236_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):4507.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4236_CR62","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.3390\/ijms14048213","volume":"14","author":"ZC Dobbin","year":"2013","unstructured":"Dobbin ZC, Landen CN. The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14(4):8213\u201327.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4236_CR63","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1158\/1078-0432.CCR-11-2485","volume":"18","author":"JK Schwarz","year":"2012","unstructured":"Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS. Pathway-specific analysis of gene expression data identifies the PI3K\/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 2012;18(5):1464\u201371.","journal-title":"Clin Cancer Res"},{"key":"4236_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2620-7","volume":"16","author":"SK Choi","year":"2016","unstructured":"Choi SK, Kim HS, Jin T, Hwang EH, Jung M, Moon WK. Overexpression of the miR-141\/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K\/AKT signaling pathways by secreting VEGF-A. BMC Cancer. 2016;16:1\u201314.","journal-title":"BMC Cancer"},{"issue":"1","key":"4236_CR65","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/1061186X.2018.1473408","volume":"27","author":"Y Guan","year":"2019","unstructured":"Guan Y, He Y, Lv S, Hou X, Li L, Song J. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K\/AKT signalling pathway. J Drug Target. 2019;27(1):60\u20136.","journal-title":"J Drug Target"},{"key":"4236_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00428-014-1588-4","volume":"465","author":"O Tapia","year":"2014","unstructured":"Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P. The PI3K\/AKT\/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 2014;465:25\u201333.","journal-title":"Virchows Arch"},{"key":"4236_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-018-0813-4","volume":"37","author":"Y Tang","year":"2018","unstructured":"Tang Y, Pan J, Huang S, Peng X, Zou X, Luo Y, et al. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K\/AKT signaling. J Exp Clin Cancer Res. 2018;37:1\u201316.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"4236_CR68","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.18632\/aging.101534","volume":"10","author":"S Gao","year":"2018","unstructured":"Gao S, Zhao Z, Wu R, Wu L, Tian X, Zhang Z. MiR-146b inhibits autophagy in prostate cancer by targeting the PTEN\/Akt\/mTOR signaling pathway. Aging. 2018;10(8):2113.","journal-title":"Aging"},{"issue":"11","key":"4236_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111347","volume":"16","author":"M Ferreira","year":"2024","unstructured":"Ferreira M, Morais M, Medeiros R, Teixeira AL. MicroRNAs as promising therapeutic agents against prostate cancer resistant to castration\u2014where are we now? Pharmaceutics. 2024;16(11):1347.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4236_CR70","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1002\/jcb.26445","volume":"119","author":"CJ Song","year":"2018","unstructured":"Song CJ, Chen H, Chen LZ, Ru GM, Guo JJ, Ding QN. The potential of microRNAs as human prostate cancer biomarkers: a meta-analysis of related studies. J Cell Biochem. 2018;119(3):2763\u201386.","journal-title":"J Cell Biochem"},{"issue":"7","key":"4236_CR71","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cellsig.2015.03.018","volume":"27","author":"JL Song","year":"2015","unstructured":"Song JL, Nigam P, Tektas SS, Selva E. MicroRNA regulation of Wnt signaling pathways in development and disease. Cell Signal. 2015;27(7):1380\u201391.","journal-title":"Cell Signal"},{"issue":"20","key":"4236_CR72","doi-asserted-by":"publisher","first-page":"33972","DOI":"10.18632\/oncotarget.15687","volume":"8","author":"S Shang","year":"2017","unstructured":"Shang S, Hua F, Hu Z-W. The regulation of \u03b2-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017;8(20):33972.","journal-title":"Oncotarget"},{"issue":"1","key":"4236_CR73","volume":"2017","author":"J Shi","year":"2017","unstructured":"Shi J, Li F, Luo M, Wei J, Liu X. Distinct roles of Wnt\/\u03b2-catenin signaling in the pathogenesis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Mediators Inflamm. 2017;2017(1):3520581.","journal-title":"Mediators Inflamm"},{"issue":"8","key":"4236_CR74","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nrurol.2012.116","volume":"9","author":"RM Kypta","year":"2012","unstructured":"Kypta RM, Waxman J. Wnt\/\u03b2-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9(8):418\u201328.","journal-title":"Nat Rev Urol"},{"key":"4236_CR75","doi-asserted-by":"crossref","unstructured":"Arend RC, Londo\u00f1o-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt\/\u03b2-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013;131(3):772\u20139.","DOI":"10.1016\/j.ygyno.2013.09.034"},{"issue":"5","key":"4236_CR76","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","volume":"51","author":"M Katoh","year":"2017","unstructured":"Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity. Int J Oncol. 2017;51(5):1357\u201369.","journal-title":"Int J Oncol"},{"issue":"23","key":"4236_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233934","volume":"11","author":"N Ben-Ghedalia-Peled","year":"2022","unstructured":"Ben-Ghedalia-Peled N, Vago R. Wnt signaling in the development of bone metastasis. Cells. 2022;11(23):3934.","journal-title":"Cells"},{"issue":"4","key":"4236_CR78","first-page":"1299","volume":"44","author":"Y Lei","year":"2020","unstructured":"Lei Y, Chen L, Zhang G, Shan A, Ye C, Liang B, Sun J, Liao X, Zhu C, Chen Y. MicroRNAs target the Wnt\/\u03b2-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer. Oncol Rep. 2020;44(4):1299\u2013313.","journal-title":"Oncol Rep"},{"issue":"2","key":"4236_CR79","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.amjms.2016.05.002","volume":"352","author":"W Si","year":"2016","unstructured":"Si W, Li Y, Shao H, Hu R, Wang W, Zhang K, Yang Q. MiR-34a inhibits breast cancer proliferation and progression by targeting Wnt1 in Wnt\/\u03b2-catenin signaling pathway. Am J Med Sci. 2016;352(2):191\u20139.","journal-title":"Am J Med Sci"},{"issue":"3","key":"4236_CR80","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/path.4097","volume":"229","author":"A Strillacci","year":"2013","unstructured":"Strillacci A, Valerii MC, Sansone P, Caggiano C, Sgromo A, Vittori L, Fiorentino M, Poggioli G, Rizzello F, Campieri M. Loss of miR-101 expression promotes Wnt\/\u03b2\u2010catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol. 2013;229(3):379\u201389.","journal-title":"J Pathol"},{"issue":"1","key":"4236_CR81","doi-asserted-by":"publisher","first-page":"8407","DOI":"10.1080\/21655979.2021.1977556","volume":"12","author":"G-L Song","year":"2021","unstructured":"Song G-L, Xiao M, Wan X-Y, Deng J, Ling J-D, Tian Y-G, Li M, Yin J, Zheng R-Y, Tang Y. MiR-130a-3p suppresses colorectal cancer growth by targeting Wnt Family Member 1 (WNT1). Bioengineered. 2021;12(1):8407\u201318.","journal-title":"Bioengineered"},{"key":"4236_CR82","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201902_16987","author":"M Xi","year":"2019","unstructured":"Xi M, Cheng L, Hua W, Zhou Y-L, Gao Q-L, Yang J-X, et al. MicroRNA-95-3p promoted the development of prostatic cancer via regulating DKK3 and activating Wnt\/\u03b2-catenin pathway. Eur Rev Med Pharmacol Sci. 2019. https:\/\/doi.org\/10.26355\/eurrev_201902_16987.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4236_CR83","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.biopha.2018.01.082","volume":"99","author":"D Wang","year":"2018","unstructured":"Wang D, Lu G, Shao Y, Xu D. MiR-182 promotes prostate cancer progression through activating Wnt\/\u03b2-catenin signal pathway. Biomed Pharmacother. 2018;99:334\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4236_CR84","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/carcin\/bgs371","volume":"34","author":"I-S Hsieh","year":"2013","unstructured":"Hsieh I-S, Chang K-C, Tsai Y-T, Ke J-Y, Lu P-J, Lee K-H, Yeh S-D, Hong T-M, Chen Y-L. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt\/beta-catenin signaling pathway. Carcinogenesis. 2013;34(3):530\u20138.","journal-title":"Carcinogenesis"},{"issue":"2","key":"4236_CR85","first-page":"3140","volume":"17","author":"Z Yu","year":"2018","unstructured":"Yu Z, Wang Z, Li F, Yang J, Tang L. MiR\u2013138 modulates prostate cancer cell invasion and migration via Wnt\/\u03b2\u2013catenin pathway. Mol Med Rep. 2018;17(2):3140\u20135.","journal-title":"Mol Med Rep"},{"issue":"3","key":"4236_CR86","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.bbrc.2015.12.054","volume":"469","author":"W Ren","year":"2016","unstructured":"Ren W, Li C, Duan W, Du S, Yang F, Zhou J, Xing J. MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7. Biochem Biophys Res Commun. 2016;469(3):633\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"4236_CR87","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00005-016-0405-y","volume":"64","author":"A Panday","year":"2016","unstructured":"Panday A, Inda ME, Bagam P, Sahoo MK, Osorio D, Batra S. Transcription factor NF-\u03baB: an update on intervention strategies. Arch Immunol Ther Exp. 2016;64:463\u201383.","journal-title":"Arch Immunol Ther Exp"},{"issue":"1","key":"4236_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010082","volume":"12","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, Shoorei H, Bahroudi Z, Hussen BM, Talebi SF, Taheri M, et al. Nrf2-related therapeutic effects of curcumin in different disorders. Biomolecules. 2022;12(1):82.","journal-title":"Biomolecules"},{"issue":"19","key":"4236_CR89","doi-asserted-by":"publisher","first-page":"9967","DOI":"10.1093\/nar\/gkz739","volume":"47","author":"MC Mulero","year":"2019","unstructured":"Mulero MC, Wang VY-F, Huxford T, Ghosh G. Genome reading by the NF-\u03baB transcription factors. Nucleic Acids Res. 2019;47(19):9967\u201389.","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"4236_CR90","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.7150\/jca.34302","volume":"10","author":"NA Espinoza-S\u00e1nchez","year":"2019","unstructured":"Espinoza-S\u00e1nchez NA, Gy\u0151rffy B, Fuentes-Panan\u00e1 EM, G\u00f6tte M. Differential impact of classical and non-canonical NF-\u03baB pathway-related gene expression on the survival of breast cancer patients. J Cancer. 2019;10(21):5191.","journal-title":"J Cancer"},{"issue":"2","key":"4236_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6020066","volume":"6","author":"M Tegowski","year":"2018","unstructured":"Tegowski M, Baldwin A. Noncanonical NF-\u03baB in cancer. Biomedicines. 2018;6(2):66.","journal-title":"Biomedicines"},{"issue":"8","key":"4236_CR92","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1096\/fj.201601263R","volume":"31","author":"Y Gu","year":"2017","unstructured":"Gu Y, Ampofo E, Menger MD, Laschke MW. Mir-191 suppresses angiogenesis by activation of NF\u2010kB signaling. FASEB J. 2017;31(8):3321\u201333.","journal-title":"FASEB J"},{"issue":"7","key":"4236_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070938","volume":"11","author":"S Hunter","year":"2019","unstructured":"Hunter S, Nault B, Ugwuagbo KC, Maiti S, Majumder M. Mir526b and Mir655 promote tumour associated angiogenesis and lymphangiogenesis in breast cancer. Cancers. 2019;11(7):938.","journal-title":"Cancers"},{"issue":"2","key":"4236_CR94","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncb1681","volume":"10","author":"Q Huang","year":"2008","unstructured":"Huang Q, Gumireddy K, Schrier M, Le Sage C, Nagel R, Nair S, et al. The micrornas miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008;10(2):202\u201310.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"4236_CR95","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1089\/dna.2015.3186","volume":"35","author":"X Kong","year":"2016","unstructured":"Kong X, Qian X, Duan L, Liu H, Zhu Y, Qi J. Microrna-372 suppresses migration and invasion by targeting p65 in human prostate cancer cells. DNA Cell Biol. 2016;35(12):828\u201335.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"4236_CR96","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/CBM-210072","volume":"35","author":"Z Lian","year":"2022","unstructured":"Lian Z, Chang T, Ma S, Li J, Zhang H, Wang X, et al. MiR-96-5p induced NDRG1 deficiency promotes prostate cancer migration and invasion through regulating the NF-\u03baB signaling pathway. Cancer Biomark. 2022;35(1):83\u201398.","journal-title":"Cancer Biomark"},{"key":"4236_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.01.015","author":"J Kang","year":"2022","unstructured":"Kang J, La Manna F, Bonollo F, Sampson N, Alberts I, Mingels C, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022. https:\/\/doi.org\/10.1016\/j.canlet.2022.01.015.","journal-title":"Cancer Lett"},{"issue":"10","key":"4236_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx034","volume":"109","author":"SB Eichm\u00fcller","year":"2017","unstructured":"Eichm\u00fcller SB, Osen W, Mandelboim O, Seliger B. Immune modulatory microRNAs involved in tumor attack and tumor immune escape. JNCI J Natl Cancer Inst. 2017;109(10):djx034.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"10","key":"4236_CR99","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.drudis.2019.06.010","volume":"24","author":"B Kulkarni","year":"2019","unstructured":"Kulkarni B, Kirave P, Gondaliya P, Jash K, Jain A, Tekade RK, et al. Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer. Drug Discov Today. 2019;24(10):2058\u201367.","journal-title":"Drug Discov Today"},{"issue":"19\u201320","key":"4236_CR100","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19\u201320):1267\u201384.","journal-title":"Genes Dev"},{"issue":"7","key":"4236_CR101","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.3390\/ijms140714240","volume":"14","author":"BN Hannafon","year":"2013","unstructured":"Hannafon BN, Ding W-Q. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013;14(7):14240\u201369.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"4236_CR102","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2014.09.004","volume":"292","author":"M Zhou","year":"2014","unstructured":"Zhou M, Chen J, Zhou L, Chen W, Ding G, Cao L. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Cell Immunol. 2014;292(1\u20132):65\u20139.","journal-title":"Cell Immunol"},{"issue":"4","key":"4236_CR103","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2014.03.007","volume":"25","author":"W Zhou","year":"2014","unstructured":"Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O\u2019Connor STF, Chin AR. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25(4):501\u201315.","journal-title":"Cancer Cell"},{"issue":"8","key":"4236_CR104","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.tranon.2019.04.014","volume":"12","author":"S Meltzer","year":"2019","unstructured":"Meltzer S, Bj\u00f8rnetr\u00f8 T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, et al. Circulating exosomal miR-141-3p and miR-375 in metastatic progression of rectal cancer. Transl Oncol. 2019;12(8):1038\u201344.","journal-title":"Transl Oncol"},{"issue":"3","key":"4236_CR105","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/dvdy.24548","volume":"247","author":"K Drak Alsibai","year":"2018","unstructured":"Drak Alsibai K, Meseure D. Tumor microenvironment and noncoding RNAs as co-drivers of epithelial\u2013mesenchymal transition and cancer metastasis. Dev Dyn. 2018;247(3):405\u201331.","journal-title":"Dev Dyn"},{"issue":"21","key":"4236_CR106","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1038\/onc.2014.212","volume":"34","author":"S Josson","year":"2015","unstructured":"Josson S, Gururajan M, Sung S, Hu P, Shao C, Zhau H, Liu C, Lichterman J, Duan P, Li Q. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene. 2015;34(21):2690\u20139.","journal-title":"Oncogene"},{"issue":"6","key":"4236_CR107","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3390\/ijms21062118","volume":"21","author":"T Lorenc","year":"2020","unstructured":"Lorenc T, Klimczyk K, Michalczewska I, S\u0142omka M, Kubiak-Tomaszewska G, Olejarz W. Exosomes in prostate cancer diagnosis, prognosis and therapy. Int J Mol Sci. 2020;21(6):2118.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4236_CR108","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1161\/ATVBAHA.112.300068","volume":"33","author":"G Liu","year":"2013","unstructured":"Liu G, Abraham E. MicroRNAs in immune response and macrophage polarization. Arterioscler Thromb Vasc Biol. 2013;33(2):170\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1737","key":"4236_CR109","doi-asserted-by":"publisher","first-page":"20160486","DOI":"10.1098\/rstb.2016.0486","volume":"373","author":"M Fabbri","year":"2018","unstructured":"Fabbri M. MicroRNAs and miRceptors: a new mechanism of action for intercellular communication. Philosophical Trans Royal Soc B: Biol Sci. 2018;373(1737):20160486.","journal-title":"Philosophical Trans Royal Soc B: Biol Sci"},{"key":"4236_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01563-7","volume":"20","author":"J Rong","year":"2020","unstructured":"Rong J, Xu L, Hu Y, Liu F, Yu Y, Guo H, Ni X, Huang Y, Zhao L, Wang Z. Inhibition of let-7b-5p contributes to an anti-tumorigenic macrophage phenotype through the SOCS1\/STAT pathway in prostate cancer. Cancer Cell Int. 2020;20:1\u201315.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4236_CR111","volume":"2022","author":"C Han","year":"2022","unstructured":"Han C, Deng Y, Xu W, Liu Z, Wang T, Wang S, et al. The roles of tumor-associated macrophages in prostate cancer. J Oncol. 2022;2022(1):8580043.","journal-title":"J Oncol"},{"key":"4236_CR112","unstructured":"Niespolo C. Investigating the Post-transcriptional Regulation of Macrophage and Prostate Cancer Transcriptome by microRNAs with focus on Tribbles-1. University of Sheffield; 2020."},{"issue":"23","key":"4236_CR113","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.3390\/cancers13236145","volume":"13","author":"FH Pottoo","year":"2021","unstructured":"Pottoo FH, Iqubal A, Iqubal MK, Salahuddin M, Rahman JU, AlHajri N, Shehadeh M. miRNAs in the regulation of cancer immune response: effect of miRNAs on cancer immunotherapy. Cancers. 2021;13(23):6145.","journal-title":"Cancers"},{"issue":"10","key":"4236_CR114","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/cr.2014.121","volume":"24","author":"Y Yin","year":"2014","unstructured":"Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, Wang Z, Chen X, Zhang W, Yokoyama S. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014;24(10):1164\u201380.","journal-title":"Cell Res"},{"issue":"1","key":"4236_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85502-4","volume":"15","author":"FM Aldakheel","year":"2025","unstructured":"Aldakheel FM, Alnajran H, Mateen A, Alduraywish SA, Alqahtani MS, Syed R. Comprehensive computational analysis of differentially expressed miRNAs and their influence on transcriptomic signatures in prostate cancer. Sci Rep. 2025;15(1):3646.","journal-title":"Sci Rep"},{"issue":"1","key":"4236_CR116","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15384047.2019.1665393","volume":"21","author":"L Zheng","year":"2020","unstructured":"Zheng L, Kang Y, Zhang L, Zou W. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR. Cancer Biol Ther. 2020;21(1):34\u201342.","journal-title":"Cancer Biol Ther"},{"key":"4236_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.660853","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, Liu KY, Liu Q, Cao Q. Androgen receptor-related non-coding RNAs in prostate cancer. Front Cell Dev Biol. 2021;9:660853.","journal-title":"Front Cell Dev Biol"},{"issue":"18","key":"4236_CR118","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1038\/onc.2015.295","volume":"35","author":"C Coarfa","year":"2016","unstructured":"Coarfa C, Fiskus W, Eedunuri VK, Rajapakshe K, Foley C, Chew SA, Shah SS, Geng C, Shou J, Mohamed JS. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene. 2016;35(18):2345\u201356.","journal-title":"Oncogene"},{"issue":"8","key":"4236_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9080102","volume":"9","author":"K-i Takayama","year":"2017","unstructured":"Takayama K-i, Misawa A, Inoue S. Significance of microRNAs in androgen signaling and prostate cancer progression. Cancers. 2017;9(8):102.","journal-title":"Cancers"},{"key":"4236_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1583255","volume":"13","author":"X Wei","year":"2025","unstructured":"Wei X, Liu R, Li W, Yu Q, Yang QT, Li T. Advances in research regarding epithelial-mesenchymal transition and prostate cancer. Front Cell Dev Biol. 2025;13:1583255.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"4236_CR121","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.1002\/jcp.27948","volume":"234","author":"SG Aghdam","year":"2019","unstructured":"Aghdam SG, Ebrazeh M, Hemmatzadeh M, Seyfizadeh N, Shabgah AG, Azizi G, Ebrahimi N, Babaie F, Mohammadi H. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol. 2019;234(7):9927\u201342.","journal-title":"J Cell Physiol"},{"issue":"1","key":"4236_CR122","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3892\/ijo.2013.1915","volume":"43","author":"B Verdoodt","year":"2013","unstructured":"Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers S-T, Palisaar R-J, et al. Microrna-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol. 2013;43(1):307\u201314.","journal-title":"Int J Oncol"},{"issue":"2","key":"4236_CR123","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/jhg.2013.121","volume":"59","author":"S Kojima","year":"2014","unstructured":"Kojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y. The tumor-suppressive microRNA-143\/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet. 2014;59(2):78\u201387.","journal-title":"J Hum Genet"},{"issue":"1","key":"4236_CR124","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.15","volume":"8","author":"M Colden","year":"2018","unstructured":"Colden M, Dar AA, Saini S, Dahiya PV, Shahryari V, Yamamura S, et al. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis. 2018;8(1):e2572\u20132572.","journal-title":"Cell Death Dis"},{"key":"4236_CR125","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lfs.2017.09.028","volume":"190","author":"Y-j Zhou","year":"2017","unstructured":"Zhou Y-j, Yang H-q, Xia W, Cui L, Xu R-f, Lu H, Xue Z, Zhang B. Tian Z-n, Cao Y-j: Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci. 2017;190:7\u201314.","journal-title":"Life Sci"},{"issue":"12","key":"4236_CR126","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.3390\/cells10123327","volume":"10","author":"Z Wang","year":"2021","unstructured":"Wang Z. Regulation of cell cycle progression by growth factor-induced cell signaling. Cells. 2021;10(12):3327.","journal-title":"Cells"},{"key":"4236_CR127","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-2736-5_1","volume-title":"Cell-cycle synchronization: methods and protocols","author":"Z Wang","year":"2022","unstructured":"Wang Z. Cell cycle progression and synchronization: an overview. In: Cell-cycle synchronization: methods and protocols. Springer US; 2022. p. 3\u201323."},{"issue":"6","key":"4236_CR128","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1530\/ERC-20-0517","volume":"28","author":"S Ben-Salem","year":"2021","unstructured":"Ben-Salem S, Venkadakrishnan VB, Heemers HV. Novel insights in cell cycle dysregulation during prostate cancer progression. Endocr Relat Cancer. 2021;28(6):R141-55.","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"4236_CR129","doi-asserted-by":"publisher","first-page":"349","DOI":"10.18632\/oncotarget.167","volume":"1","author":"EJ Noonan","year":"2010","unstructured":"Noonan EJ, Place RF, Basak S, Pookot D, Li L-C. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget. 2010;1(5):349.","journal-title":"Oncotarget"},{"issue":"12","key":"4236_CR130","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/pros.23871","volume":"79","author":"RK Nam","year":"2019","unstructured":"Nam RK, Benatar T, Wallis CJ, Kobylecky E, Amemiya Y, Sherman C, Seth A. MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. Prostate. 2019;79(12):1435\u201351.","journal-title":"Prostate"},{"key":"4236_CR131","doi-asserted-by":"crossref","unstructured":"Orafidiya F, Deng L, Bevan CL, Fletcher CE. Crosstalk between long non coding RNAs, microRNAs and DNA damage repair in prostate cancer: new therapeutic opportunities? Cancers 2022, 14(3):755.","DOI":"10.3390\/cancers14030755"},{"issue":"2","key":"4236_CR132","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.gene.2015.07.017","volume":"572","author":"L Wang","year":"2015","unstructured":"Wang L, Liu C, Li C, Xue J, Zhao S, Zhan P, et al. Effects of microRNA-221\/222 on cell proliferation and apoptosis in prostate cancer cells. Gene. 2015;572(2):252\u20138.","journal-title":"Gene"},{"key":"4236_CR133","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.biopha.2018.10.098","volume":"109","author":"S Gao","year":"2019","unstructured":"Gao S, Zhao Z, Wu R, Wu L, Tian X, Zhang Z. MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt\/mTOR signaling pathway by binding to c-Met. Biomed Pharmacother. 2019;109:1406\u201310.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4236_CR134","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbrc.2008.09.086","volume":"377","author":"Y Fujita","year":"2008","unstructured":"Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377(1):114\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"4236_CR135","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/cells8111455","volume":"8","author":"S Sur","year":"2019","unstructured":"Sur S, Steele R, Shi X, Ray RB. MiRNA-29b inhibits prostate tumor growth and induces apoptosis by increasing bim expression. Cells. 2019;8(11):1455.","journal-title":"Cells"},{"issue":"2","key":"4236_CR136","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.eururo.2015.12.054","volume":"70","author":"L Fabris","year":"2016","unstructured":"Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. The potential of microRNAs as prostate cancer biomarkers. Eur Urol. 2016;70(2):312\u201322.","journal-title":"Eur Urol"},{"issue":"10","key":"4236_CR137","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/jcm4101853","volume":"4","author":"T Miyazaki","year":"2015","unstructured":"Miyazaki T, Ikeda K, Sato W, Horie-Inoue K, Okamoto K, Inoue S. MicroRNA library-based functional screening identified androgen-sensitive miR-216a as a player in bicalutamide resistance in prostate cancer. J Clin Med. 2015;4(10):1853\u201365.","journal-title":"J Clin Med"},{"issue":"5","key":"4236_CR138","first-page":"4299","volume":"17","author":"J Lin","year":"2019","unstructured":"Lin J, Lu Y, Zhang X, Mo Q, Yu L. Effect of miR-200c on proliferation, invasion and apoptosis of prostate cancer LNCaP cells. Oncol Lett. 2019;17(5):4299\u2013304.","journal-title":"Oncol Lett"},{"issue":"6","key":"4236_CR139","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.3390\/ijms23062926","volume":"23","author":"H Gujrati","year":"2022","unstructured":"Gujrati H, Ha S, Mohamed A, Wang B-D. MicroRNA-mRNA regulatory network mediates activation of mTOR and VEGF signaling in African American prostate cancer. Int J Mol Sci. 2022;23(6):2926.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4236_CR140","doi-asserted-by":"publisher","DOI":"10.1111\/and.14016","volume":"53","author":"W Zhao","year":"2021","unstructured":"Zhao W, Ning L, Wang L, Ouyang T, Qi L, Yang R, et al. MiR-21 inhibition reverses doxorubicin\u2010resistance and inhibits PC3 human prostate cancer cells proliferation. Andrologia. 2021;53(5):e14016.","journal-title":"Andrologia"},{"issue":"3","key":"4236_CR141","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cellsig.2015.01.001","volume":"27","author":"H Liu","year":"2015","unstructured":"Liu H, Yin J, Wang H, Jiang G, Deng M, Zhang G, Bu X, Cai S, Du J, He Z. FOXO3a modulates WNT\/\u03b2-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal. 2015;27(3):510\u20138.","journal-title":"Cell Signal"},{"issue":"40","key":"4236_CR142","doi-asserted-by":"publisher","first-page":"67626","DOI":"10.18632\/oncotarget.18795","volume":"8","author":"SM Egan","year":"2017","unstructured":"Egan SM, Karasik E, Ellis L, Gollnick SO. MiR-30e* is overexpressed in prostate cancer and promotes NF-\u03baB-mediated proliferation and tumor growth. Oncotarget. 2017;8(40):67626.","journal-title":"Oncotarget"},{"key":"4236_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0688-6","volume":"16","author":"D Ren","year":"2017","unstructured":"Ren D, Yang Q, Dai Y, Guo W, Du H, Song L, Peng X. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-\u03baB signaling pathway. Mol Cancer. 2017;16:1\u201316.","journal-title":"Mol Cancer"},{"key":"4236_CR144","doi-asserted-by":"publisher","first-page":"9725","DOI":"10.1007\/s13277-014-2206-4","volume":"35","author":"S Zhao","year":"2014","unstructured":"Zhao S, Ye X, Xiao L, Lian X, Feng Y, Li F, et al. MiR-26a inhibits prostate cancer progression by repression of Wnt5a. Tumor Biol. 2014;35:9725\u201333.","journal-title":"Tumor Biol"},{"issue":"4","key":"4236_CR145","doi-asserted-by":"publisher","first-page":"e10147","DOI":"10.1371\/journal.pone.0010147","volume":"5","author":"Q Dong","year":"2010","unstructured":"Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F, et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One. 2010;5(4):e10147.","journal-title":"PLoS One"},{"issue":"1","key":"4236_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0556-9","volume":"15","author":"Y Wang","year":"2016","unstructured":"Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, et al. MiR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016;15(1):70.","journal-title":"Mol Cancer"},{"issue":"1","key":"4236_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0813-4","volume":"37","author":"Y Tang","year":"2018","unstructured":"Tang Y, Pan J, Huang S, Peng X, Zou X, Luo Y, et al. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K\/AKT signaling. J Exp Clin Cancer Res. 2018;37(1):160.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4236_CR148","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/CBM-210072","volume":"35","author":"Z Lian","year":"2022","unstructured":"Lian Z, Chang T, Ma S, Li J, Zhang H, Wang X, et al. MiR-96-5p induced NDRG1 deficiency promotes prostate cancer migration and invasion through regulating the NF-\u03ba B signaling pathway. Cancer Biomark. 2022;35(1):83\u201398.","journal-title":"Cancer Biomark"},{"issue":"1","key":"4236_CR149","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12935-020-01563-7","volume":"20","author":"J Rong","year":"2020","unstructured":"Rong J, Xu L, Hu Y, Liu F, Yu Y, Guo H, et al. Inhibition of let-7b-5p contributes to an anti-tumorigenic macrophage phenotype through the SOCS1\/STAT pathway in prostate cancer. Cancer Cell Int. 2020;20(1):470.","journal-title":"Cancer Cell Int"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04236-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:21:36Z","timestamp":1775571696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04236-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4236"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04236-z","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}